NCT04256252View on ClinicalTrials.gov

Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2020

Study Completion Date

June 30, 2020

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Rituximab

A scheduled therapeutic regimen with low-dose rituximab was performed.

All Listed Sponsors
lead

Tang-Du Hospital

OTHER

NCT04256252 - Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) | Biotech Hunter | Biotech Hunter